Delayed release cysteamine bead formulation, and methods of making and using same
View Patent ↗An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.
1. A pharmaceutical dosage form, comprising delayed-release cysteamine beads, the beads comprising:
(i) a core particle comprising cysteamine or a pharmaceutically acceptable salt thereof and a binder, and
(ii) an enteric membrane surrounding the core particle,
wherein the beads have a distribution of particle sizes in a range of about 0.7 mm to about 2.8 mm;
wherein the enteric membrane begins to dissolve within a pH range of about 4.5 to about 6.5;
wherein the enteric membrane is present in an amount in a range of about 25% to about 35% by weight, based on the weight of the core particles; and
wherein the pharmaceutical dosage form, upon administration in a capsule to fasted healthy normal subjects at 600 mg free cysteamine base, provides:
(a) a mean Cmax upon oral dosing in a range of 2.3±0.6 mg/L or in a range of 80% to 125% thereof; and
(b) a mean AUC (0-inf_D) upon oral dosing in a range of 0.84±0.19 min*mg/L/mg or in a range of 80% to 125% thereof.
2. The pharmaceutical composition of claim 1 , wherein the particle sizes of the beads are in a range of about 0.7 mm to about 2.5 mm.
3. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by at least 80% by weight of the beads having a particle size in a range of about 850 μm to about 1180 μm.
4. The pharmaceutical composition of claim 1 , wherein 5% or less of the beads by weight are retained on a #12 mesh (1.68 mm) screen and 10% or less by weight pass through a #20 mesh (0.84 mm) screen.
5. The pharmaceutical composition of claim 1 , wherein the distribution of bead sizes is characterized by less than 5% by weight of the beads being retained on a 1400 μm sieve.
6. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by less than 30% by weight of the beads being retained on a 1180 μm sieve.
7. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by less than 70% by weight of the beads being retained on a 1000 μm sieve.
8. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by less than 20% by weight of the beads being retained on a 850 μm sieve.
9. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by at least 15% by weight of the beads being retained on a 1180 μm sieve.
10. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by at least 50% by weight of the beads being retained on a 1000 μm sieve.
11. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by at least 10% by weight of the beads being retained on a 850 μm sieve.
12. The pharmaceutical dosage form of claim 1 , wherein the distribution of bead sizes is characterized by a median particle size in a range of about 850 μm to about 1180 μm.
13. The pharmaceutical dosage form of claim 1 , wherein the bead core particle further comprises a filler.
14. The pharmaceutical dosage form of claim 1 , wherein the cysteamine (as free base) is present in the bead core particle in an amount of at least 10 wt. %.
15. The pharmaceutical dosage form of claim 1 , wherein the cysteamine or pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of cysteamine.
16. The pharmaceutical dosage form of claim 1 , wherein 5% or less of the bead core particles by weight are retained on a #12 mesh (1.68 mm) screen and 10% or less by weight pass through a #20 mesh (0.84 mm) screen.
17. The pharmaceutical dosage form of claim 1 , wherein the enteric-coated beads are characterized by acid resistance such that not more than 10% of the cysteamine in the beads is dissolved after a period of two hours in a 0.1N HCl solution.
18. The pharmaceutical dosage form of claim 1 , wherein the enteric-coated beads are characterized by dissolution such that 80% of the cysteamine or pharmaceutically acceptable salt thereof is released within 20 minutes in a solution buffered at pH 6.8.
19. The pharmaceutical dosage form of claim 1 , further comprising a capsule shell enclosing the plurality of beads.
20. The pharmaceutical dosage form of claim 1 , wherein the beads provide a mean Cmax and mean AUC (0-inf_D) upon oral dosing, fasted, when administered inside a capsule shell that are bioequivalent to the mean Cmax and mean AUC (0-inf_D) upon oral dosing, fasted, when administered without a capsule shell.
21. The pharmaceutical dosage form of claim 1 , wherein the enteric membrane comprises an enteric material that begins to dissolve at pH of about 5.5 in an aqueous solution.
22. The pharmaceutical dosage form of claim 1 , wherein the pharmaceutical dosage form, upon administration in a capsule to fasted healthy normal subjects at 600 mg free cysteamine base, provides:
(a) a mean Cmax upon oral dosing in a range of 2.3±0.6 mg/L; and
(b) a mean AUC (0-inf_D) upon oral dosing in a range of 0.84±0.19 min*mg/L/mg.
23. The pharmaceutical dosage form of claim 1 , wherein the pharmaceutical dosage form, upon administration in a capsule to fasted healthy normal subjects at 600 mg free cysteamine base, provides:
(a) a mean Cmax upon oral dosing of 2.3 mg/L or in a range of 80% to 125% thereof; and
(b) a mean AUC (0-inf_D) upon oral dosing of 0.84 min*mg/L/mg or in a range of 80% to 125% thereof.